Jornal Internacional de Desenvolvimento e Pesquisa de Drogas

  • ISSN: 0975-9344
  • Índice h do diário: 44
  • Pontuação de citação de diário: 59.93
  • Fator de impacto do periódico: 48.80
Indexado em
  • Genamics JournalSeek
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • CiteFactor
  • Scimago
  • Diretório de Indexação de Periódicos de Pesquisa (DRJI)
  • OCLC- WorldCat
  • publons
  • MIAR
  • Comissão de Bolsas Universitárias
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEU
  • Laboratórios secretos do mecanismo de pesquisa
  • ResearchGate
Compartilhe esta página

Abstrato

Targeting Tumour Blood Vessels with a Liposomal Drug Delivery system for Cancer Treatment

Naghmeh Shahraki*

By providing various drug delivery methods and controlled-release distribution tactics, nanotechnology provides an alternative to traditional treatment alternatives. Due to their high biodegradability and general lack of toxicity, liposomes provide a flexible platform for a number of various delivery strategies that may improve the distribution and targeting of medicines to tumours. Due to fenestrated blood arteries within tumours, liposomes spontaneously enter tumours, causing recognised increased permeability and associated medication retention effects. Liposomes are appealing carriers for molecular imaging applications because they can be utilised to transport radioactive moieties, such as radiotracers, which can be bound at various points inside liposomes. Using the phage display method, various high-affinity and selectivity peptides can be delivered to various targets. In this study, covalent peptide-PEG-PE anchors were used to link gelatinase-binding peptides discovered by phage display to liposomes, resulting in a tailored drug delivery vehicle. A good approach for tumour targeting is to use gelatinases as extracellular targets. Based on our research, focused drug delivery outperforms non-targeted drug delivery in terms of effectiveness.

Keywords

Liposome; Transparent tumor; Blood vessels; Nanotechnology; Anticancer agents; Targeted drug delivery

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado